Skip to main content

Table 3 Outcome (mortality) in TTS patients

From: Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy

Variables No catecholamines (n = 93) catecholamines
(n = 21)
Relative risk (95% CI) p value *
In-hospital mortality 3 (3.22) 6 (28.57) (1.0–6.5) < 0.01
30-day mortality 3 (2.15) 6 (28.57) (1.0–6.5) < 0.01
1-year mortality 6 (6.45) 8 (38.09) (1.1–3.7) < 0.01
2-year mortality 11 (11.82) 10 (47.61) (1.1–2.5) < 0.01
3-year mortality 12 (12.90) 11 (52.38) (1.1–2.5) < 0.01
4-year mortality 18 (19.35) 11 (52.38) (1.0–1.9) < 0.01
Long-term mortality 20 (21.50) 13 (61.90) (1.1–2.0) < 0.01
  1. *p values for the comparison between no catecholamines and catecholamines